Geron cancer drug meets midstage study goals

Courtesy Newsvine - business  Tue, 12/08/2009 - 17:06

Biotechnology company Geron Corp. said Tuesday its developing cancer treatment GRNVAC1 met safety and tolerability goals in a midstage study.


 

Related items

Bristol-Myers: Liver cancer drug failed in study
A key experimental liver cancer drug that Bristol-Myers Squibb Co. has been testing did not meet the main goal of a late-stage study.

Retiring Amgen CEO Kevin Sharer to Hand Role to...
Kevin Sharer, who has run Amgen Inc., the world's largest biotechnology company, for the past decade, will hand the reins to Robert Bradway, president and chief operating officer, in May.

Erlotinib effective and with fewer side-effects after...
(European Society for Medical Oncology) The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer...

Samsung SCX-4200 3-in-1 True Multifunction Printer
The SCX-4200 Digital Productivity Center is a low cost black and white laser printer, delivering 3 in 1 true multifunction performance with professional laser output.Keep your valuable real...

BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
The X5 Stereo Bluetooth Headset is a portable multi-function device utilizing the latest cutting edge technologies allowing you to stream high quality music and make voice calls using a...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com